Menu
A screenshot of the presidential proclamation announcing the tariffs
The Trump administration announced on April 2 that pharmaceutical manufacturers will face new tariffs unless they negotiate a "most favored nation" price and begin to onshore their production of drugs.

White House Announces Tariffs on Drugmakers That Do Not Negotiate MFN Prices, U.S. Manufacturing Commitments

Luke Zarzecki, National Correspondent 340B Report Views
The White House unveiled plans last week to set 100% tariffs on brand-name imported drugs with a number of exceptions, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Trump’s FY 27 HHS Budget Again Looks to Move 340B from HRSA to CMS, Calls for Major OPA Funding Increase

CMS Extends Deadline for Hospitals to Complete Medicare Drug Cost Survey with Significant 340B Implications

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live